title: Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yemen cohort of the A1chieve study.
abstract: BACKGROUND
  The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents.
  
  
  METHODS
  Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Yemen.
  
  
  RESULTS
  A total of 104 patients were enrolled in the study. Three different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (n = 94), insulin aspart (n = 4), basal insulin plus insulin aspart (n = 1) and other insulin combinations (n = 2). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 10.6%) and insulin user (mean HbA1c: 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA1c (insulin naïve: -2.7%, insulin users: -1.8%). SADR's including major hypoglycaemia events did not occur in any of the study patients.
  
  
  CONCLUSIONS
  Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
authors.affiliation: Department of Internal Medicine, Al Thwarh & Private Clinic, Sanaa, Yemen.
authors.forename: Zayed
authors.initials: Z
authors.lastname: Atef
authors.affiliation: Department of Internal Medicine, Al Thwarh & Private Clinic, Sanaa, Yemen.
authors.forename: Abdulkareem
authors.initials: A
authors.lastname: Al-Khawlany
authors.affiliation: Department of Internal Medicine, Al Thwarh & Private Clinic, Sanaa, Yemen.
authors.forename: Abdalla A
authors.initials: AA
authors.lastname: Gunaid
keywords: A1chieve study; Yemen; insulin analogues; type 2 diabetes mellitus